Executive leadership at JUPITER NEUROSCIENCES.
Board of directors at JUPITER NEUROSCIENCES.
Research analysts covering JUPITER NEUROSCIENCES.
Recent press releases and 8-K filings for JUNS.
Jupiter Neurosciences, Inc. Stockholders Approve Increase in Authorized Shares and 2025 Equity Incentive Plan
JUNS
Proxy Vote Outcomes
Executive Compensation
Board Change
- Jupiter Neurosciences, Inc. held its 2025 Annual Meeting of Stockholders on December 19, 2025, where several key proposals were approved.
- Stockholders approved an amendment to the Certificate of Incorporation, increasing the authorized common stock from 125,000,000 to 500,000,000 shares.
- The 2025 Equity Incentive Plan was approved, making 5,250,000 shares of common stock available for delivery under the plan.
- Other approvals included the election of seven director nominees, the ratification of Cherry Bekaert LLC as the independent auditor, and the potential issuance of shares under the Standby Equity Purchase Agreement (SEPA) with Yorkville.
Dec 22, 2025, 9:30 PM
Jupiter Neurosciences Secures Up to $20 Million in Flexible Financing
JUNS
Debt Issuance
New Projects/Investments
Convertible Preferred Issuance
- Jupiter Neurosciences, Inc. (JUNS) entered into agreements on October 24, 2025, with an affiliate of Yorkville Advisors Global, LP, for up to $20 million in flexible financing.
- The financing comprises a $6 million pre-paid advance (with an initial $4 million funded at signing on October 24, 2025, at a fixed conversion price of $1.50) and an additional $14 million available through a Standby Equity Purchase Agreement (SEPA) over 24 months.
- JUNS intends to use the proceeds to support its Phase 2 Parkinson's trial for JOTROL™ and accelerate the growth of its Nugevia™ product line.
- As consideration for Yorkville's commitment, JUNS paid a $25,000 structuring fee and issued 131,909 shares of Common Stock, valued at $200,000.
Oct 27, 2025, 9:25 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more